Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerald P Radich

Showing results (171-180 of 208) with videos related to

Pageof 21
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2005
Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemiaMohamed L Sorror, Michael B Maris, Brenda M Sandmaier, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 19, 2007
Chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Kapil Bhalla, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 7, 2012
Chronic myelogenous leukemiaSusan O'Brien, Camille N Abboud, Mojtaba Akhtari, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 3, 2009
NCCN clinical practice guidelines in oncology: chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Hossein Borghaei, et al.
Blood|August 1, 2002
Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndromeH Joachim Deeg, Barry Storer, John T Slattery, et al.
Haematologica|February 2, 2023
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysisJerald P Radich, Matthew Wall, Susan Branford, et al.
Blood|December 1, 2007
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemiaPhilipp le Coutre, Oliver G Ottmann, Francis Giles, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 15, 2013
Chronic Myelogenous Leukemia, Version 1.2014Susan O'Brien, Jerald P Radich, Camille N Abboud, et al.
Blood|January 9, 2010
Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AMLJessica A Pollard, Todd A Alonzo, Robert B Gerbing, et al.
The Journal of Molecular Diagnostics : JMD|May 17, 2025
Analytical Performance of the NCI-myeloMATCH Assay: A Rapid Turnaround Genomic Profiling Assay for Myeloid DisordersCecilia Cs Yeung, Srikrishna K Narava, Ting-Chia Chang, et al.
Pageof 21

Showing results (171-180 of 208) with videos related to

Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2005
Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemiaMohamed L Sorror, Michael B Maris, Brenda M Sandmaier, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 19, 2007
Chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Kapil Bhalla, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 7, 2012
Chronic myelogenous leukemiaSusan O'Brien, Camille N Abboud, Mojtaba Akhtari, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 3, 2009
NCCN clinical practice guidelines in oncology: chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Hossein Borghaei, et al.
Blood|August 1, 2002
Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndromeH Joachim Deeg, Barry Storer, John T Slattery, et al.
Haematologica|February 2, 2023
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysisJerald P Radich, Matthew Wall, Susan Branford, et al.
Blood|December 1, 2007
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemiaPhilipp le Coutre, Oliver G Ottmann, Francis Giles, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 15, 2013
Chronic Myelogenous Leukemia, Version 1.2014Susan O'Brien, Jerald P Radich, Camille N Abboud, et al.
Blood|January 9, 2010
Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AMLJessica A Pollard, Todd A Alonzo, Robert B Gerbing, et al.
The Journal of Molecular Diagnostics : JMD|May 17, 2025
Analytical Performance of the NCI-myeloMATCH Assay: A Rapid Turnaround Genomic Profiling Assay for Myeloid DisordersCecilia Cs Yeung, Srikrishna K Narava, Ting-Chia Chang, et al.
Pageof 21